This study presents a multi-routed research design featuring thiadiazole/ oxadiazole based Schiff base derivatives as potential inhibitors, targeting cancer and Alzheimer. Among thiadiazole based Schiff base derivatives, the excellent inhibition was exhibited by compound 1 (IC50 = 20.10 ± 1.1, 22.21 ± 1.03 and 26.23 ± 2.2 µM for HepG2 (liver cancer), MCF-7 (breast cancer) and W138 (lung cancer), respectively) in comparison to the standard Doxorubicin. Oxadiazole based compound 9 was also found with spellbinding efficacy (IC50 =15.20 ± 2.5, 19.13 ± 2.2 and 12.33 ± 3.4 µM for HepG2, MCF-7 and W138, respectively). Both compounds 1(IC50=3.10 ± 0.20 and 3.70 ± 0.10 µM against AChE and BuChE) and 9 (IC50=2.20 ± 0.10 and 2.80 ± 0.50 µM against AChE and BuChE) were also found as excellent anti-Alzheimer agents in comparison to reference donepezil. The outcomes of in vitro biological activity were further studied in silico via molecular docking, DFT and ADMET to elucidate the binding interactions, stability, reactivity and pharmacokinetic profiles of potent compounds.
Read full abstract